Shots:

• The company discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab). The biosimilars are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and Serum Institute of India
• The disclosure demonstrates NeuClone’s ability to develop multiple biosimilars simultaneously through its NeuMAX platform
• Additionally- NeuClone and Serum Institute are developing eight other biosimilars including clinical-stage candidates referencing Stelara (ustekinumab) and Herceptin (trastuzumab)

­ Ref: PRNewswire | Image: Pharmaceutical Daily